Cover Image

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Chun‐Chieh Chen, Shiuan‐Chih Chen
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks—Authors' Reply
by: Rui Huang, et al.
Published: (2025)

Letter: Late Diagnosis of Chronic Hepatitis B—Quantifying the Missed Opportunities and Clinical Consequences
by: Bi‐Yu Gao, et al.
Published: (2025)

Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL‐B Study
by: Rui Huang, et al.
Published: (2025)

Letter on “Immigration Factors and Monitoring of Chronic Hepatitis B Infection Among Foreign‐Born: The FOCUS‐HBV Multicentre Cohort”
by: Dong Hyun Kim, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’
by: Dong Hyun Kim, et al.
Published: (2025)

Letter on “Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China”
by: Ersel Bilgin, et al.
Published: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
by: Tyng‐Yuan Jang, et al.
Published: (2025)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
by: Jia‐Ling Wu, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
by: Ning Yu, et al.
Published: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
by: Ying‐Nan Tsai, et al.
Published: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
by: YaoYao Dai, et al.
Published: (2025)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
by: Benedikt Silvester Hofer, et al.
Published: (2026)

Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses
by: Changhu Sun, et al.
Published: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis
by: Ewan Forrest, et al.
Published: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
by: Maria Buti
Published: (2025)

Editorial: Chronic Hepatitis B at the Intersection of Immigration, Acculturation and Social Determinants of Health
by: Thomas Hoang, et al.
Published: (2025)

Virological and Immunological Characteristics of HBeAg ‐Positive Chronic Hepatitis B Patients With Low HBsAg Levels
by: Yuxin Chen, et al.
Published: (2024)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
by: Pei‐Chien Tsai, et al.
Published: (2025)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
by: Yan Liu, et al.
Published: (2025)

Letter on ‘Unveiling Drug‐Induced Autoimmune‐Like Hepatitis in Autoimmune Hepatitis Patients: A Multicenter Retrospective Study’
by: Muhammad Ibrahim Khalil, et al.
Published: (2025)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
by: Luisa Bertin, et al.
Published: (2026)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
by: Francisco Idalsoaga, et al.
Published: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
by: Ying‐Nan Tsai, et al.
Published: (2025)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
by: Grace Lai‐Hung Wong, et al.
Published: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
by: Jian Wang, et al.
Published: (2025)

Editorial: Low‐Level Viraemia in Chronic Hepatitis B—A Benign State or Missed Opportunity?
by: Miriam T. Levy
Published: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
by: Yu Jun Wong
Published: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations. Authors' Reply
by: Yuxin Chen, et al.
Published: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations
by: Zhen Deng, et al.
Published: (2025)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
by: Yi‐Ping Hung, et al.
Published: (2024)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
by: Muhammad Osama, et al.
Published: (2024)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
by: Xingfei Pan, et al.
Published: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
by: Yash Hegde, et al.
Published: (2026)

Increased Risk for Liver Disease in Patients With Chronic Hepatitis B Virus Infection and Low‐Level Viraemia
by: Paul Y. Kwo, et al.
Published: (2026)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy—Authors' Reply
by: Tanat Saeoui, et al.
Published: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
by: Pinelopi Arvaniti, et al.
Published: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
by: Alberto Ferrarese, et al.
Published: (2025)

Letter: Refining Mortality Estimates in Severe Alcohol‐Associated Hepatitis—Addressing Heterogeneity and Prognostic Assessment
by: Shupeng Zhao, et al.
Published: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
by: Lukas Burghart, et al.
Published: (2026)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
by: Anupam Kumar Singh, et al.
Published: (2026)